Adverse Event Reporting News - Factive tablets
May 6, 2008 -- PRECAUTIONS Rash Moderate to severe photosensitivity/ phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions...
Business Wire - Regulatory Filing for FACTIVE Tablets Submitted in Europe
May 7, 2008 -- Oscient Pharmaceuticals' partner, Menarini Group, seeks marketing approval for fluoroquinolone antibiotic WALTHAM, Mass. -- Oscient Pharmaceuticals...
Crain's Cleveland Business - MDSS switches to Factivity moniker.(Small Business)
May 14, 2007 -- MDSS, a 23-year-old Cleveland company specializing in information systems for manufacturing companies, has changed its name to Factivity Inc....
Biotech Business - OSCIENT COMPLETES ENROLLMENT IN PHASE IV OF FACTIVE TABLETS.
March 1, 2007 -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI), Waltham, Mass., has completed enrollment in its Phase IV post-marketing trial for its...
Pharma Marketletter - Factive effective for CAP and ABECB
August 16, 2004 -- Two new studies published in the August issue of Respiratory Medicine show that Oscient Pharmaceutical's Factive (gemifloxacin mesylate) is effective...
Business Wire - Metaldyne Implements MDSS FACTIVITY
March 22, 2004 -- Business Editors/High-Tech Writers CLEVELAND--(BUSINESS WIRE)--March 22, 2004 A leading global designer and supplier of metal-based components,...
M2 Presswire - Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia Receives FDA Approval.
May 2, 2007 -- M2 PRESSWIRE-2 May 2007-Making The Watchlist: Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia...
Business Wire - Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in Canada
March 2, 2007 -- Fluoroquinolone antibiotic now available for the treatment of AECB MONTREAL and WALTHAM, Mass. -- Abbott Canada, the Canadian affiliate of Abbott,...
Business Wire - Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
January 26, 2007 -- Post-marketing FORCE trial completed ahead of schedule WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has completed...
Business Wire - Oscient Pharmaceuticals and Menarini Group Enter into European Commercialization Agreement for FACTIVE Tablets
January 4, 2007 -- -- Leading European Pharmaceutical Company Joins Global Commercialization Effort -- WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq:...
